Recent advances of small-molecule Mcl-1 inhibitors or degraders as promising anti-cancer agents (2018-present)
- 21 August 2025
- journal article
- review article
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 299, 118079
Abstract
No abstract availableKeywords
Funding Information
- Hunan Provincial Natural Science Foundation (2023JJ30270)
- Scientific Research Foundation of Hunan Provincial Education Department (24A0358)
- National Natural Science Foundation of China (82003602)
- National Natural Science Foundation of China (22277025)
This publication has 104 references indexed in Scilit:
- 1‐Sulfonylated 1,2,3,4‐tetrahydroquinoline‐6‐carboxylic acids as simple, readily‐accessible MCL‐1 inhibitorsDrug Development Research, 2022
- Identification of bicyclic compounds that act as dual inhibitors of Bcl-2 and Mcl-1Molecular Diversity, 2022
- Recent progress in biologically active indole hybrids: a mini reviewPharmacological Reports, 2022
- Design, synthesis, stereochemical determination, molecular docking study, in silico pre-ADMET prediction and anti-proliferative activities of indole-pyrimidine derivatives as Mcl-1 inhibitorsBioorganic Chemistry, 2021
- Drimane Derivatives as the First Examples of Covalent BH3 Mimetics that Target MCL‐1ChemMedChem, 2021
- Discovery of novel indazole-acylsulfonamide hybrids as selective Mcl-1 inhibitorsBioorganic Chemistry, 2020
- Discovery and development of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives as Bcl-2/Mcl-1 inhibitorsBioorganic Chemistry, 2019
- Discovery of selective Mcl-1 inhibitors via structure-based design and structure-activity relationship analysisBiochemical and Biophysical Research Communications, 2019
- Modular PROTAC Design for the Degradation of Oncogenic BCR‐ABLAngewandte Chemie International Edition, 2015
- Development of 3‐Phenyl‐N‐(2‐(3‐phenylureido)ethyl)‐thiophene‐2‐sulfonamide Compounds as Inhibitors of Antiapoptotic Bcl‐2 Family ProteinsChemMedChem, 2014